Abstract
We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
References
Boubenider S, Hiesse C, Goupy C et al. Incidences and consequences of post-transplantation lymphoproliferative disorders J Nephrol 1997 10: 136 145
Swinnen LJ . Diagnosis and treatment of transplant-related lymphoma Ann Oncol 2000 11: (Suppl. 1) S45 S48
Lones MA, Kirov I, Said JW et al. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient Bone Marrow Transplant 2000 26: 1021 1024
Anderson KC, Soiffer R, DeLage R et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications Blood 1990 76: 235 244
Shepard JD, Gascoyne RD, Barnett MJ et al. Polyclonal Epstein–Barr virus associated lymphoproliferative disorder following autografting for chronic myeloid leukemia Bone Marrow Transplant 1995 15: 639 641
Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens Bone Marrow Transplant 1999 23: 111 117
Nolte A, Buhmann, Straka C et al. Assessment and characterization of the cytolytic T lymphocyte response against Epstein–Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1998 21: 909 916
Briz M, Fores R, Regidor C et al. Epstein–Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukemia Br J Haematol 1997 98: 485 487
Young L, Alfieri C, Hennessy K et al. Expression of Epstein–Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease New Engl J Med 1989 321: 1080 1085
Chao NJ, Berry GJ, Advani R et al. Epstein–Barr virus associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma Transplantation 1993 55: 1425 1428
Hauke RJ, Greiner TC, Smir BN et al. Epstein–Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases Bone Marrow Transplant 1998 21: 1271 1274
Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998 16: 2052 2059
Sakai Y, Ohga S, Tonegawa Y et al. Interferon-alpha therapy for chronic active Epstein–Barr virus infection: potential effect on the development of T-lymphoproliferative disease J Pediatr Hematol Oncol 1998 20: 342 346
Davis CL . The antiviral prophylaxis of post-transplant lymphoproliferative disorder Springer Semin Immunopathol 1998 20: 437 453
Pirsch JD, Stratta RJ, Sollinger HW et al. Treatment of severe Epstein–Barr virus induced lymphoproliferative syndrome with gancyclovir: two cases after solid organ transplantation Am J Med 1989 86: 241 244
Yufu Y, Kimura M, Kawano R et al. Epstein–Barr virus associated lymphoproliferative disorder following autologous blood stem cell transplantation for relapsed Hodgkin's disease Bone Marrow Transplant 2000 26: 1339 1341
Faro A . Interferon-alpha and its effects on post-transplant lymphoproliferative disorders Springer Semin Immunopathol 1998 20: 425 436
Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gamma globulin New Engl J Med 1988 318: 1334
O'Brien S, Bernert RA, Logan JL, Lien YH . Remission of posttransplant lymphoproliferative disorder after interferon alpha treatment J Am Soc Nephrol 1997 8: 1483 1489
Davis CL, Wood BL, Sabath DE et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants Transplantation 1998 66: 1770 1779
Kluin-Nelemans HC, Kester MG, van de Corput L et al. Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia Blood 1998 91: 4224 4231
Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation New Engl J Med 1991 324: 1451 1456
Milpied N, Antoine C, Garnier JL et al. Humanized anti-CD 20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders (B PTLDs): a retrospective analysis of 32 patients Ann Oncol 2000 11: (Suppl. 1) 113 116
Kuehnle I, Huls MH, Semmelmann M et al. CD 20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation Blood 2000 95: 1502 1505
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jenkins, D., DiFrancesco, L., Chaudhry, A. et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant 30, 321–326 (2002). https://doi.org/10.1038/sj.bmt.1703603
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bmt.1703603
Keywords
This article is cited by
-
T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein–Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma
Diagnostic Pathology (2020)
-
Post-transplant lymphoproliferative disorder manifesting as lymphomatoid granulomatosis: report of two cases and review of the literature highlighting current challenges in pathologic classification
Journal of Hematopathology (2019)
-
Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma
BMC Cancer (2005)
-
T-cell large granular lymphocytic leukemia occurring after autologous peripheral blood stem cell transplantation
Bone Marrow Transplantation (2004)
-
T-cell post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation: another case and a review of the literature
Bone Marrow Transplantation (2004)


